MARKET

PACB

PACB

PacBio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.695
+0.090
+2.50%
After Hours: 3.700 +0.005 +0.14% 17:54 05/27 EDT
OPEN
3.660
PREV CLOSE
3.605
HIGH
3.715
LOW
3.460
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
7.04
52 WEEK LOW
2.200
MARKET CAP
569.28M
P/E (TTM)
-10.7444
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PACB stock price target is 5.00 with a high estimate of 6.00 and a low estimate of 4.000.

EPS

PACB News

More
Edited Transcript of PACB earnings conference call or presentation 6-May-20 8:30pm GMT
Q1 2020 Pacific Biosciences of California Inc Earnings Call
Thomson Reuters StreetEvents · 05/17 22:01
Pacific Biosciences of California Inc (PACB) Q1 2020 Earnings Call Transcript
Earlier today, we issued a press release outlining the financial results we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or alternatively as furnished on the Form 8-K available on the
Motley Fool · 05/07 15:30
Pacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/07 02:10
Pacific Biosciences of California EPS beats by $0.17, misses on revenue
Pacific Biosciences of California (NASDAQ:PACB): Q1 GAAP EPS of $0.01 beats by $0.17. Revenue of $15.6M (-5.1% Y/Y) misses by $4.03M. Press Release
seekingalpha · 05/07 01:05
Pacific Biosciences of California, Inc. Announces First Quarter 2020 Financial Results
GlobeNewswire · 05/06 21:03
Pacific Biosciences Q1 EPS $0.010 May Not Compare To $(0.160) Estimate, Sales $15.598M Miss $20.070M Estimate
Pacific Biosciences (NASDAQ:PACB) reported quarterly earnings of $0.010 per share which beat the analyst consensus estimate of $(0.160) by 106.25 percent. This is a 105 percent increase over losses of $(0.200) per share
Benzinga · 05/06 20:33
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 14:36
ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss
Zacks · 04/30 15:30

Industry

Advanced Medical Equipment & Technology
+0.72%
Healthcare Equipment & Supplies
+0.73%

Hot Stocks

Symbol
Price
%Change

About PACB

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.
More

Webull offers kinds of Pacific Biosciences of California Inc stock information, including NASDAQ:PACB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PACB stock news, and many more online research tools to help you make informed decisions.